Side-by-side comparison of AI visibility scores, market position, and capabilities
Teaneck NJ IT services (NASDAQ: CTSH) $19.7B FY2024 revenue; Belcan engineering $1.3B acquisition, GenAI 100+ engagements, NextGen transformation competing with Infosys, Wipro, and Accenture.
Cognizant Technology Solutions Corporation is a Teaneck, New Jersey-based information technology services and consulting company — publicly traded on the NASDAQ (NASDAQ: CTSH) as an S&P 500 Information Technology component — providing IT services, digital transformation consulting, cloud migration, enterprise application management, and business process outsourcing through approximately 340,000 employees primarily in India (Chennai, Hyderabad, Pune delivery centers) serving clients in financial services, healthcare, manufacturing, and communications sectors in North America, Europe, and the rest of world. In fiscal year 2024, Cognizant reported revenues of $19.7 billion with modest growth as the IT services sector emerged from the 2023 discretionary spending slowdown, with the company's NextGen strategy (investing in generative AI services, cloud-native application transformation, and digital operations) driving bookings growth. CEO Ravi Kumar S. — joined January 2023 from Infosys — has executed a talent and client engagement restructuring focused on "moving up the value chain" from labor-arbitrage IT outsourcing toward higher-value consulting and AI-integration services: the Belcan acquisition ($1.3 billion, 2023) added 5,500 engineering services professionals serving US aerospace and defense customers (Boeing, Lockheed Martin, General Dynamics), expanding Cognizant beyond IT services into engineering R&D outsourcing. Cognizant's generative AI practice (partnering with Google Cloud, Microsoft Azure, AWS for GenAI implementation) grew to 100+ active GenAI client engagements by 2024 as enterprise clients deployed AI copilots, process automation, and customer service chatbots on Cognizant-managed cloud infrastructure.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.